Özmen Vahit, Atasoy Ajlan, Gökmen Erhan, Özdoğan Mustafa, Güler Nilufer, Uras Cihan, Ok Engin, Demircan Orhan, Işıkkdoğan Abdurrahman, Cabioğlu Neslihan, Şen Fatma, Saip Pınar
Department of General Surgery, İstanbul University İstanbul School of Medicine, İstanbul, Turkey.
Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, İstanbul, Turkey.
J Breast Health. 2016 Jul 1;12(3):107-111. doi: 10.5152/tjbh.2016.2874. eCollection 2016 Jul.
Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aimed to evaluate the correlations between Recurrence Score (RS) and routine risk factors.
Ten academic centers across Turkey participated in this prospective trial. Consecutive patients with breast cancer who had pT1-3, pN0-N1mic, ER-positive, and HER2-negative tumors were identified at tumor conferences. Both pre- and post-RS treatment decisions and physician perceptions were recorded on questionnaire forms. Correlations between RS and classic risk factors were evaluated using univariate and multivariate analyses.
Ten centers enrolled a total of 165 patients. The median tumor size was 2 cm. Of the 165 patients, 57% had low RS, 35% had intermediate RS, and 8% had high RS, respectively. Multivariate analysis indicated that progesterone receptor (PR) and Ki67 scores were significantly related to RS.
Oncotype DX Recurrence Score does not seem to have a significant correlation with the majority of classic risk factors, but it may have a correlation with PR score and Ki67 score.
乳腺癌是土耳其女性中最常见的恶性肿瘤,且早期疾病的发生率正在上升。Oncotype DX 21基因检测可预测雌激素受体(ER)阳性、人表皮生长因子受体2(HER2)阴性早期乳腺癌的远处复发。我们旨在评估复发评分(RS)与常规风险因素之间的相关性。
土耳其的10个学术中心参与了这项前瞻性试验。在肿瘤会议上确定了连续的乳腺癌患者,这些患者的肿瘤为pT1-3、pN0-N1mic、ER阳性且HER2阴性。RS治疗前后的决策以及医生的看法都记录在问卷表上。使用单变量和多变量分析评估RS与经典风险因素之间的相关性。
10个中心共纳入165例患者。肿瘤大小中位数为2厘米。在这165例患者中,分别有57%的患者RS较低,35%的患者RS中等,8%的患者RS较高。多变量分析表明,孕激素受体(PR)和Ki67评分与RS显著相关。
Oncotype DX复发评分似乎与大多数经典风险因素没有显著相关性,但可能与PR评分和Ki67评分相关。